Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

The novel prostate cancer antigen 3 (PCA3) biomarker.

Bourdoumis A, Papatsoris AG, Chrisofos M, Efstathiou E, Skolarikos A, Deliveliotis C.

Int Braz J Urol. 2010 Nov-Dec;36(6):665-8; discussion 669. Review.

2.

Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.

Sciarra A, Panebianco V, Cattarino S, Busetto GM, De Berardinis E, Ciccariello M, Gentile V, Salciccia S.

BJU Int. 2012 Dec;110(11):1661-5. doi: 10.1111/j.1464-410X.2012.11146.x. Epub 2012 May 4.

3.

The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population.

Shen M, Chen W, Yu K, Chen Z, Zhou W, Lin X, Weng Z, Li C, Wu X, Tao Z.

Exp Mol Pathol. 2011 Feb;90(1):97-100. doi: 10.1016/j.yexmp.2010.10.009. Epub 2010 Oct 20.

PMID:
20970419
4.

PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.

Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, Groskopf J.

Urology. 2007 Mar;69(3):532-5.

PMID:
17382159
5.

APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.

Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, Cass M, Hodge P, Macairan ML, Marks LS, Rittenhouse H.

Clin Chem. 2006 Jun;52(6):1089-95. Epub 2006 Apr 20.

6.

PCA3: a molecular urine assay for predicting prostate biopsy outcome.

Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H, Groskopf J.

J Urol. 2008 Apr;179(4):1587-92. doi: 10.1016/j.juro.2007.11.038. Epub 2008 Mar 4.

PMID:
18295257
7.

The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance.

van Gils MP, Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SL, Witjes JA, Cornel EB, Karthaus HF, Smits GA, Dijkman GA, Mulders PF, Schalken JA.

Clin Cancer Res. 2007 Feb 1;13(3):939-43.

8.

PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.

Rigau M, Morote J, Mir MC, Ballesteros C, Ortega I, Sanchez A, Colás E, Garcia M, Ruiz A, Abal M, Planas J, Reventós J, Doll A.

Prostate. 2010 Dec 1;70(16):1760-7. doi: 10.1002/pros.21211.

PMID:
20672322
9.

Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.

Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, Haese A, Schalken J, Stenzl A, Tombal B, van der Poel H.

Eur Urol. 2011 Nov;60(5):1045-54. doi: 10.1016/j.eururo.2011.08.003. Epub 2011 Aug 25. Review.

PMID:
21871709
10.

The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?

Ploussard G, Haese A, Van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Bastien L, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, Van Gils MP, Schalken JA, de La Taille A.

BJU Int. 2010 Oct;106(8):1143-7. doi: 10.1111/j.1464-410X.2010.09286.x.

11.

Molecular PCA3 diagnostics on prostatic fluid.

van Gils MP, Cornel EB, Hessels D, Peelen WP, Witjes JA, Mulders PF, Rittenhouse HG, Schalken JA.

Prostate. 2007 Jun 1;67(8):881-7.

PMID:
17440939
12.

PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.

Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, Davis JW, Troncoso P, Rittenhouse H, Babaian RJ.

J Urol. 2008 May;179(5):1804-9; discussion 1809-10. doi: 10.1016/j.juro.2008.01.013. Epub 2008 Mar 18.

PMID:
18353398
13.

Progensa™ PCA3 test for prostate cancer.

Durand X, Moutereau S, Xylinas E, de la Taille A.

Expert Rev Mol Diagn. 2011 Mar;11(2):137-44. doi: 10.1586/erm.10.122.

PMID:
21405964
14.

PCA3: from basic molecular science to the clinical lab.

Day JR, Jost M, Reynolds MA, Groskopf J, Rittenhouse H.

Cancer Lett. 2011 Feb 1;301(1):1-6. doi: 10.1016/j.canlet.2010.10.019. Epub 2010 Nov 18. Review.

PMID:
21093148
15.

[Value of PCA3 urinary test for prostate biopsy decision: the Lyon-Sud University Hospital experience].

Vlaeminck-Guillem V, Campos-Fernandes JL, Champetier D, Chikh K, Decaussin-Petrucci M, Devonec M, Gobeaux N, Paparel P, Perrin P, Rodriguez-Lafrasse C, Ruffion A.

Ann Biol Clin (Paris). 2011 Jan-Feb;69(1):31-9. doi: 10.1684/abc.2010.0513. French.

16.

PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting.

Shappell SB, Fulmer J, Arguello D, Wright BS, Oppenheimer JR, Putzi MJ.

Urology. 2009 Feb;73(2):363-8. doi: 10.1016/j.urology.2008.08.459. Epub 2008 Nov 8.

PMID:
18995890
17.

The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting.

Adam A, Engelbrecht MJ, Bornman MS, Manda SO, Moshokoa E, Feilat RA.

BJU Int. 2011 Dec;108(11):1728-33. doi: 10.1111/j.1464-410X.2011.10202.x. Epub 2011 Apr 20.

18.

A three-gene panel on urine increases PSA specificity in the detection of prostate cancer.

Rigau M, Ortega I, Mir MC, Ballesteros C, Garcia M, Llauradó M, Colás E, Pedrola N, Montes M, Sequeiros T, Ertekin T, Majem B, Planas J, Ruiz A, Abal M, Sánchez A, Morote J, Reventós J, Doll A.

Prostate. 2011 Dec;71(16):1736-45. doi: 10.1002/pros.21390. Epub 2011 Apr 25.

PMID:
21520154
19.

PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.

Ramos CG, Valdevenito R, Vergara I, Anabalon P, Sanchez C, Fulla J.

Urol Oncol. 2013 Nov;31(8):1522-6. doi: 10.1016/j.urolonc.2012.05.002. Epub 2012 Jun 9.

PMID:
22687565
20.

PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.

Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, Petrovics G, Ibrahim M, Elsamanoudi S, Cullen J, Sesterhenn IA, Brassell S, Rittenhouse H, Srivastava S, McLeod DG.

J Urol. 2008 Nov;180(5):1975-8; discussion 1978-9. doi: 10.1016/j.juro.2008.07.060. Epub 2008 Sep 17.

PMID:
18801539

Supplemental Content

Support Center